United States securities and exchange commission logo





                            June 26, 2020

       Eric A. Adams
       President and Chief Executive Officer
       InMed Pharmaceuticals Inc.
       Suite 310-815 W. Hastings Street
       Vancouver, B.C. V6C 1B4
       Canada

                                                        Re: InMed
Pharmaceuticals Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed June 19, 2020
                                                            File No. 333-239319

       Dear Mr. Adams:

              We have reviewed your registration statement and have the
following comment. In our
       comment, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to the comment, we may have additional comments.

       Registration Statement on Form S-1 filed on June 19, 2020

       Business
       Our Product Candidates and Technologies
       Key Milestones, page 79

   1.                                                   We note your response
to comment 3. It appears that your Collaborative Research
                                                        Agreement with the
University of British Columbia is material to your business. Please
                                                        disclose in the Summary
section that such agreement may be terminated by either party
                                                        upon 30 calendar days'
written notice, as referenced on page 79.
 Eric A. Adams
InMed Pharmaceuticals Inc.
June 26, 2020
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Ibolya Ignat at 202-551-3636 or Terence O'Brien at
202-551-3355 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Christine Westbrook at 202-551-5019
with any other
questions.



                                                           Sincerely,
FirstName LastNameEric A. Adams
                                                           Division of
Corporation Finance
Comapany NameInMed Pharmaceuticals Inc.
                                                           Office of Life
Sciences
June 26, 2020 Page 2
cc:       Daniel M. Miller, Esq.
FirstName LastName